Sugi Predict

Sugi Predict / Targets / ATR

ATR

Serine/threonine-protein kinase ATR · Q13535 · ATR on Sugi Atlas →

91,200 patent compounds predicted against ATR, 43,674 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL318797 SCHEMBL318797 0.68 19/20
Benzoic Acid Benzoic Acid (SCHEMBL412075) 0.58 14/20
SCHEMBL336653 SCHEMBL336653 0.53 14/20
SCHEMBL441294 SCHEMBL441294 0.51 14/20
SCHEMBL411951 SCHEMBL411951 0.75 12/20
SCHEMBL439516 SCHEMBL439516 0.53 12/20
SCHEMBL373050 SCHEMBL373050 0.56 11/20
SCHEMBL373051 SCHEMBL373051 0.56 11/20
SCHEMBL373052 SCHEMBL373052 0.56 11/20
SCHEMBL373155 SCHEMBL373155 0.44 11/20
SCHEMBL373156 SCHEMBL373156 0.44 11/20
SCHEMBL373157 SCHEMBL373157 0.44 11/20
SCHEMBL411424 SCHEMBL411424 0.56 10/20
SCHEMBL319167 SCHEMBL319167 0.56 10/20
SCHEMBL247192 SCHEMBL247192 0.47 10/20
SCHEMBL411857 SCHEMBL411857 0.67 9/20
SCHEMBL413176 SCHEMBL413176 0.64 9/20
SCHEMBL407802 SCHEMBL407802 0.57 9/20
SCHEMBL410132 SCHEMBL410132 0.56 9/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL411390) 0.56 9/20

Clinical trials — most relevant to ATR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
Study Of ATRN-119 In Patients With Advanced Solid Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors PHASE1/PHASE2RECRUITING
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs PHASE1/PHASE2NOT_YET_RECRUITING
M6620 (VX-970) in Selected Solid Tumors PHASE2COMPLETED
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia PHASE2COMPLETED
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia PHASE2COMPLETED
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer PHASE2ACTIVE_NOT_RECRUITING
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer PHASE2COMPLETED
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss PHASE2ACTIVE_NOT_RECRUITING
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency PHASE2COMPLETED
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Phase 1 Study of ATR-002 PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer PHASE1COMPLETED
Phase I Study of FXS887 in the Treatment of Solid Tumors PHASE1NOT_YET_RECRUITING
First-in-human Single and Multiple Dose Trial of ATR-258 PHASE1COMPLETED
Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours PHASE1UNKNOWN
M6620 Plus Standard Treatment in Oesophageal and Other Cancer PHASE1COMPLETED
AZD6738 for Patients With Progressive MDS or CMML PHASE1ACTIVE_NOT_RECRUITING
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer PHASE1ACTIVE_NOT_RECRUITING
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas PHASE1COMPLETED
AZD6738 & Gemcitabine as Combination Therapy PHASE1UNKNOWN
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ATR binder may also engage these)

ProteinNameSimilarity
Q9JKK8 — 1.000 Q9JKK8 →
Q9DE14 — 1.000 Q9DE14 →
Q6CAD2 — 1.000 Q6CAD2 →
A1Z8X3 — 1.000 A1Z8X3 →
Q8BKX6 — 0.999 Q8BKX6 →
Q9FKS4 — 0.998 Q9FKS4 →
E1C231 — 0.998 E1C231 →
P97313 — 0.997 P97313 →
PI4KA Phosphatidylinositol 4-kinase alpha 0.997 landscape →
O14715 — 0.997 O14715 →
Q5MNV8 — 0.997 Q5MNV8 →
Q9DEI1 — 0.997 Q9DEI1 →
Q9VXG8 — 0.997 Q9VXG8 →
O08662 — 0.997 O08662 →
F4I893 — 0.997 F4I893 →
P32333 — 0.997 P32333 →
Q99666 — 0.997 Q99666 →
GEMIN4 Gem-associated protein 4 0.997 landscape →
SMG1 Serine/threonine-protein kinase SMG1 0.997 landscape →
P42173 — 0.997 P42173 →
Q9SXA1 — 0.997 Q9SXA1 →
C5J7W8 — 0.996 C5J7W8 →
Q70PP2 — 0.996 Q70PP2 →
Q18892 — 0.996 Q18892 →
Q751Y8 — 0.996 Q751Y8 →
O02811 — 0.996 O02811 →
Q9C8Z4 — 0.996 Q9C8Z4 →
Q7Z3J3 — 0.996 Q7Z3J3 →
P0DJD0 — 0.996 P0DJD0 →
Q80UK8 — 0.996 Q80UK8 →